Is it fair for the government to pressure companies to provide compassionate access to new therapies when their own formal evaluation processes appear to be showing very little urgency when it comes to patient access?
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 March
March 27, 2026 - - Podcast -
The unseen price of survival for women facing early breast cancer in Australia
March 27, 2026 - - Latest News -
This is the not so quiet demand and doctrine of rationed health care
March 27, 2026 - - Latest News -
If these can be presented as positives, then we really have become accustomed to terrible
March 26, 2026 - - Latest News -
Liberty expands into Asia Pacific life sciences insurance with new tailored offering
March 25, 2026 - - Australian Biotech -
Budget delivers progress, but hundreds of thousands still waiting for access
March 25, 2026 - - Latest News -
To what extent does the system even see itself as bound by external review?
March 25, 2026 - - Latest News
